We noticed you’re blocking ads

Thanks for visiting CRSToday. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

In order to avoid adverse performance issues with this site, please white list https://crstoday.com in your ad blocker then refresh this page.

Need help? Click here for instructions.

Up Front | April 2026

The First Win Is On The Surface

Key Takeaways

  • Ocular surface disease management belongs at the start of cataract and refractive surgical planning because tear film instability makes preoperative measurements unreliable, reduces refractive accuracy, degrades postoperative visual quality, and compromises patient satisfaction. Stable ocular surface data support a sound surgical plan from the outset.
  • Patients with ocular surface disease often lack classic dry eye symptoms and instead attribute blur, glare, fluctuating vision, irritation, or reduced visual quality to cataract, a cloudy capsule, or an imperfect surgical result. Early tangible improvement builds trust in the diagnosis and strengthens treatment adherence.
  • Long-term, multifaceted ocular surface disease management gains traction when patients experience an early win in comfort or visual quality, a milestone that supports reliable measurements before surgery and reassures dissatisfied patients after surgery. Newer therapies and treatment strategies make these early wins more achievable.

Guidance on ocular surface disease (OSD) management is plentiful. Cataract and refractive surgeons understand how tear film instability can affect preoperative measurements, the refractive accuracy of surgical intervention, patients’ postoperative quality of vision, and, ultimately, their satisfaction. We also know how common OSD is in our patient population. For many of us, however, the ocular surface remains a secondary consideration—something to address after measurements are taken, the IOL is chosen, or a patient returns dissatisfied.

In an era defined by refractive precision and patient-reported outcomes, the ocular surface can no longer be an afterthought. It is foundational to surgical planning and success. If the ocular surface is unstable, the data are unreliable, and the surgical plan is compromised from the start.

The challenge is not just identifying OSD but educating patients about it. Many of them do not think they have dry eye disease because they lack the classic symptoms. They attribute the blur, glare, fluctuating vision, irritation, or reduced visual quality they have been experiencing to a cataract, a cloudy capsule, or an imperfect surgical result. When we explain that an unhealthy ocular surface is the cause, they may not believe us immediately. That is why early wins matter.

OSD management is often long-term and multifaceted, and its success depends on patient adherence to treatment protocols. Meaningful results may take time, but when patients experience an early, tangible improvement in their comfort or visual quality, they are more likely to trust the diagnosis, follow through with treatment, and commit to the longer-term therapies that many of them require. This is an important milestone before surgery, when reliable measurements are required, and it may be even more important after surgery, when an unhappy patient needs reassurance that the source of their problem has been identified and can be addressed.

Newer therapies and treatment strategies have made these early wins more achievable, which has simplified OSD management considerably for many of us. The disease has not become less complex, but patients who feel better quickly are more willing to stay engaged with the full treatment plan.

Managing OSD is key to delivering an excellent surgical outcome. Addressing OSD earlier, more consistently, and in ways that help our patients recognize improvement quickly may be the simplest win in the entire surgical journey.

An AI language model (Claude, Anthropic) was used to assist with manuscript writing. All content was reviewed, verified, and revised by the author, who assumes full responsibility for the accuracy and integrity of the manuscript.

Advertisement - Issue Continues Below
Publication Ad Publication Ad
End of Advertisement - Issue Continues Below

April 2026